Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options-Reference-Cited by-同舟云学术

Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options

Published:2019-08 Issue:10199 Volume:394 Page:697-708
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Ray Kausik K,Corral Pablo,Morales Enrique,Nicholls Stephen J

Publisher

Elsevier BV

Subject

General Medicine

Reference101 articles.

1. Clofibrate and niacin in coronary heart disease;Stamler;JAMA,1975

2. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin;Canner;J Am Coll Cardiol,1986

3. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia;Frick;N Engl J Med,1987

4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S);Lancet,1994

5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group;Shepherd;N Engl J Med,1995

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of optimized new Shengmai powder on cardiomyocyte apoptosis and ferroptosis in ischemic heart failure rats: The mediating role of phosphatidylinositol-3-kinase/protein kinase B/tumor protein 53 signaling pathway;Journal of Ethnopharmacology;2024-08

2. Novel approaches to treat primary hyperlipidemia;American Journal of Biopharmacy and Pharmaceutical Sciences;2024-08-01

3. Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease;European Journal of Epidemiology;2024-07-15

4. Medical effectiveness and cost-effectiveness of a multidisciplinary team-based approach to the management of community residents with hypertension: an analysis of an interventional follow-up study;2024-05-24

5. Assessment of genetic and clinical factors in T2D susceptibility among patients with hypertension;Acta Diabetologica;2024-05-20